June 3, 2020
Dr. Katherine Beaverson has been elected as new Chair of the IRDiRC Company Constituent Committee (CCC), she is the Patient Advocacy Director for the Rare Disease Research Unit at Pfizer.
The IRDiRC CCC brings together representatives from the for-profit pharmaceutical and biotech that work together to identify common bottlenecks to expedite the execution of rare disease research in the company space and promote collaborations on competitive aspects of research as well as its development.
Dr. Baeverson, in her leadership role at Pfizer, interfaces with several key stakeholders driving IRDiRC’s mission to advance rare diseases research worldwide: rare disease patient organizations, scientific researchers and pharmaceutical industry capabilities and resources.
Her election as CCC Chair will further cathalize IRDiRC‘s effort towards expanding participation by industry in order to realize the shared mission to enable all people living with rare disease to receive and accurate diagnosis, care, and available therapy within one year of coming to medical attention. In addition, Dr Baeverson will ensure significant advancements on IRDiRC’s mission by joining the forces in order to solve the challenges facing rare disease research.